Commentary|Videos|November 20, 2026

Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

In the phase 3 DeLLphi-305 trial (NCT06211036), first-line maintenance tarlatamab-dlle (Imdelltra) plus durvalumab (Imfinzi) improved median overall survival to 21.1 months vs 12.7 months with durvalumab alone (HR, 0.42; 95% CI, 0.32-0.54; P <.001) in patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed after initial chemoimmunotherapy.1,2

Anne Chiang, MD, PhD, spoke with CancerNetwork® about a presentation she gave at the 44th Annual Chemotherapy Foundation Symposium (CFS®), hosted by Physicians’ Education Resource®, LLC, “Small Cell Updates: Steps Backward, Leaps Forward.” She highlighted which developments in SCLC she considers leaps forward and which she considers steps backward, including the phase 3 LAGOON trial (NCT05153239) of lurbinectedin (Zepzelca).3,4

Chiang is an associate professor of Medicine in the Section of Medical Oncology; associate cancer center director of Clinical Initiatives; and vice chief of Clinical Affairs, Medical Oncology and Hematology at Yale School of Medicine.

Transcript:

CancerNetwork: Which developments in SCLC do you see as “leaps forward,” and which as “steps backward”?

Chiang: We have some major leaps forward, and the one I was referring to is the results of the DeLLphi-305 trial with tarlatamab. That’s a bispecific DLL3 and CD3 antibody that was shown in a positive phase 3 trial at the [2026 European Society for Medical Oncology (ESMO) Congress] to have a pretty significant overall survival benefit. [There is] a major progression-free and overall survival benefit for our patients if you add this bispecific in maintenance. This is a huge leap forward for our patients. It’s taking an active agent, tarlatamab, from the second-line setting and moving it up into the maintenance setting.

Some of the other leaps forward include updates at ESMO for DeLLphi-304 [NCT05740566], the second-line trial, which showed with more follow-up that the tails of the curve demonstrate a sustained benefit for overall survival and progression-free survival with tarlatamab.5 Also very exciting is the follow-up for the DeLLphi-303 trial [NCT05361395], a phase 1 study using [tarlatamab plus either atezolizumab or durvalumab] after 4 cycles of chemotherapy induction, where the median overall survival is somewhere in the range of 30 to 38 months.6 That tells us that using tarlatamab, a T-cell engager that targets a surface protein on the cancer cell, really makes a difference, probably in a tumor type that is immune cold.

As far as steps backward, lurbinectedin is a cytotoxic chemotherapy that has been used in the second and third line and had accelerated FDA approval for that. Because of the negative LAGOON trial, and a press release that said lurbinectedin monotherapy did worse than topotecan in the control arm, the drug was withdrawn by the sponsor for that indication.3,4 That’s a step backward. I think lurbinectedin was a good tool, and it’s probably still a good tool for certain patients if we can figure out the biomarker. But certainly, the T-cell engagers are moving our field leaps forward. Some of those numbers are as good as you see in some non–small cell lung cancer trials, and some of the hazard ratios, like 0.3 or 0.4 for PFS and OS in DeLLphi-305, are just amazing.

References

  1. Sands J, Yoshida T, Ahn MJ, et al. Tarlatamab plus durvalumab vs durvalumab as first-line maintenance therapy following first-line durvalumab, platinum, and etoposide in extensive-stage small cell lung cancer: primary analysis of the phase 3 DeLLphi-305 trial. Presented at: European Society for Medical Oncology (ESMO) Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA3.
  2. Pérol M, Yoshida T, Ahn MJ, et al. Tarlatamab-durvalumab maintenance for extensive-stage small-cell lung cancer. N Engl J Med. Published online October 24, 2026. doi:10.1056/NEJMoa2609482
  3. Jazz Pharmaceuticals provides update on Zepzelca (lurbinectedin) phase 3 LAGOON trial in second-line small cell lung cancer. News release. Jazz Pharmaceuticals plc. June 12, 2026. Accessed November 20, 2026. https://tinyurl.com/2dcu42hvJazz
  4. Jazz Pharmaceuticals announces second quarter 2026 financial results. News release. Jazz Pharmaceuticals plc. August 3, 2026. Accessed November 20, 2026. https://tinyurl.com/47na5nnd
  5. Rudin CM, Ahn MJ, Schuler M, et al. Tarlatamab in previously treated SCLC: extended follow-up of overall survival from the phase 3 DeLLphi-304 trial. Presented at: European Society for Medical Oncology (ESMO) Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract 3808O.
  6. Wermke M, Ahn M-J, Moskovitz MT, et al. Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study. Presented at: European Society for Medical Oncology (ESMO) Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract 3821P.

Related to this article